Clinical trials
Sarcoma clinical trials
Below are recruiting sarcoma clinical trials, each written for real people, not researchers. We’re tracking 412 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
Miami, FloridaAges 18–90 - NCT06753136Recruiting
Electrochemotherapy for internal organ tumors
This trial tests a treatment called electrochemotherapy for tumors in internal organs (like the liver or pancreas) when standard treatments are no longer possible. It uses a drug called bleomycin plus electric pulses to target cancer cells.
PadovaAges 18–99 - NCT06774729Recruiting
Predicting tumor spread using MRI in sarcoma or bone cancer
This trial uses MRI scans to create a model that may predict if a musculoskeletal tumor is spreading. It aims to help doctors decide on the best surgical treatment.
BolognaAges 18 years+ - NCT06789666Recruiting
Digital art therapy for young cancer survivors
This trial is testing a digital art therapy program designed to help young adults who survived childhood cancer feel better emotionally. You'll use an app to create art and connect with others, all from home.
Chapel Hill, North CarolinaAges 18–25 - NCT06805019Recruiting
Using CT scans to tell apart uterine sarcoma from fibroids
This study uses AI to look at CT scans from women with uterine sarcomas or fibroids to see if it can tell the difference between the two. The goal is to help doctors make a faster, more accurate diagnosis without needing surgery.
Bologna, BolognaAges 18–80 - NCT06884618RecruitingPhase 1
Study of RO7673396 for advanced solid tumors with RAS mutations
This trial tests a new drug, RO7673396, for people with advanced solid tumors that have a RAS mutation. The goal is to see if the drug is safe and works against the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06935864Recruiting
Study of KLF4 and KLF7 in bone tumors
This study looks at two proteins, KLF4 and KLF7, in bone tumor samples. It aims to understand their role in osteosarcoma and Ewing sarcoma, which may help develop better treatments.
CairoAges 1 month–39 years - NCT06939855RecruitingPhase 2
QL1706 for advanced bone and soft tissue sarcoma
This trial tests an experimental drug called QL1706 for people with advanced sarcoma (a type of cancer that starts in bones or soft tissues like muscle or fat) that cannot be removed by surgery or has spread. The goal is to see if QL1706 can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06942143RecruitingPhase 1
Super1 TCR-T for NY-ESO-1 positive advanced solid tumors
This trial tests an experimental treatment called Super1 TCR-T, which is a type of immunotherapy designed to attack tumors that have a specific protein (NY-ESO-1). It is for people with advanced solid tumors whose first treatment has stopped working and who also have a certain genetic marker (HLA-A*02).
Guangzhou, GaungdongAges 18–75 - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06946225RecruitingPhase 1
Combination cell therapy for advanced melanoma or sarcoma
This trial tests a combination of two medicines: one that trains your immune cells to find cancer (ACTengine IMA203) and another that helps the body recognize the tumor (mRNA-4203). It's for people with advanced melanoma or synovial sarcoma who have already tried other treatments.
San Francisco, CaliforniaAges 18 years+ - NCT06957431RecruitingPhase 1
Zanzalintinib and eribulin for advanced leiomyosarcoma and liposarcoma
This trial tests a combination of two drugs, zanzalintinib and eribulin, for people with advanced leiomyosarcoma or liposarcoma that has progressed after prior treatment. The goal is to see if this combination can help shrink or slow the growth of these sarcomas.
St Louis, MissouriAges 18 years+ - NCT06967961Recruiting
Looking for cancer cells that carry two markers in the blood
This trial is studying a special type of cell that shows up in the blood of people with certain advanced cancers. It aims to find out if these cells can help doctors better understand the cancer and guide treatment.
ToulouseAges 18 years+ - NCT06988475RecruitingPhase 2/Phase 3
Capmatinib for cancers with MET gene changes
This study tests an oral drug called capmatinib for people whose cancers have specific changes in the MET gene (except for one type of lung cancer). It aims to see if the drug can shrink tumors or slow their growth.
BelfastAges 18 years+ - NCT07048249RecruitingEarly Phase 1
Romiplostim to prevent low platelets in Ewing sarcoma
This trial tests a platelet-boosting medicine called romiplostim to prevent dangerously low platelet counts caused by chemotherapy in children with newly diagnosed Ewing sarcoma. It is designed for patients who do not have cancer spread to the bone marrow and have not taken similar platelet drugs before.
Phoenix, ArizonaAges 1 year+ - NCT07054944Recruiting
Lymph node mapping for children with solid tumors
This study is testing a new way to map lymph nodes in children with solid tumors. It helps doctors understand how tumors spread to lymph nodes, which may guide treatment.
Rochester, New YorkAges 1 month–17 years - NCT07058064Recruiting
Watch study for heart monitoring in lymphoma or sarcoma patients
This study uses a wearable device to monitor heart health in people treated for lymphoma or sarcoma. It aims to detect heart changes early, which may help prevent long-term heart problems.
Rochester, MinnesotaAges 18 years+ - NCT07064018RecruitingPhase 1/Phase 2
SPEDOX-6 for advanced solid tumors
This trial tests a new form of the chemotherapy drug doxorubicin, called SPEDOX-6, for people with certain advanced solid tumors that haven't responded to at least two prior treatments. The drug is designed to deliver doxorubicin directly to cancer cells while possibly reducing side effects.
Orange, CaliforniaAges 18 years+ - NCT07067255RecruitingPhase 1/Phase 2
Sequential CAR-T cells for advanced ovarian cancer with CD146 and GPC3
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
Beijing, Beijing MunicipalityAges 21–90 - NCT07104331RecruitingPhase 2
Testing nab-sirolimus for epithelioid hemangioendothelioma
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
Stanford, CaliforniaAges 18 years+ - NCT07104955Recruiting
Study on software to improve team meetings
This trial tests a new software tool designed to help medical teams work together more effectively and safely during multi-disciplinary meetings. If you are part of a medical team that holds these meetings, your participation could help improve how decisions are made.
LondonAges Any age - NCT07112989Recruiting
Building lab models for sarcoma and cancer spread
This study aims to create new laboratory models to better understand sarcomas and cancers that have spread to the bone or lungs. By using donated tumor tissue and blood, researchers hope to learn how these cancers grow and develop, which could lead to better treatments in the future.
BolognaAges Up to 85 years - NCT07125183RecruitingPhase 2
Weekly chemo for advanced leiomyosarcoma in older adults
This trial tests whether weekly doxorubicin is effective and tolerable for people aged 65 and older with advanced or metastatic leiomyosarcoma. It may be a good option if you have not had this type of chemo before.
Aurora, ColoradoAges 65–100 - NCT07129317Recruiting
Pediatric radiation therapy registry
This study collects information from children and young adults who are getting radiation therapy to help improve future treatments. It looks at how radiation affects the body over time.
Washington D.C., District of ColumbiaAges birth–26 years
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sarcoma?
- Yes. Clin2 currently lists 412 recruiting sarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.